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INTRODUCTION
Parkinson’s disease (PD) is a multisys-
temic neurodegenerative disease that af-
fects selected nuclei of the medulla ob-
longata and pons, olfactory bulb and
tract, intestinal ganglionic plexus, sub-
stantia nigra pars compacta, amygdala,
nucleus basalis of Meynert and cerebral
cortex. The main neuropathological hall-
mark is the presence of intraneuronal in-
clusions named Lewy bodies (LB) and
aberrant neurites (LN) filled with abnor-
mal protein aggregates, of which the
most important component is α-synuclein,
which is abnormally phosphorylated,
 nitrated and oxidized and shows abnor-
mal solubility, aggregation and facility to
fibril formation (1–3). Classic PD is mani-
fested as a complex motor disorder that
results from the reduced dopaminergic
input of the substantia nigra to the stria-
tum and the resultant altered basal gan-
glia modulation of motor control (4).
Cases with Lewy body pathology in the
brain stem without motor symptoms are
considered as having incidental PD (iPD)
because they are unexpectedly discov-
ered after appropriate postmortem neu-
ropathological study (5–8). Whether
these cases constitute premotor PD has
been a matter of controversy for some
years, because it cannot be confirmed
that these cases would have progressed
to Parkinsonism if they had survived
longer. However, the study of consecu-
tive cases in a large series and the recog-
nition of several intermediate degrees of
involvement of the brain stem, limbic
structures and, eventually, the cerebral
cortex make it clear that a prediction of
iPD as an anterior stage of PD seems
more than reasonable (2,9–11).
Cortical involvement in PD has long
been neglected. Yet cognitive impair-
ment occurs in most cases with ad-
vanced PD. More importantly, altered
cortical function can be detected in some
individuals before the appearance of
motor symptoms, and cortical dysfunc-
tion is common in classic Parkinsonism
when appropriately examined (12). Re-
cent neuroimaging approaches have
supported the involvement of the cere-
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Lipid rafts are cholesterol- and sphingomyelin-enriched microdomains that provide a highly saturated and viscous physico-
chemical microenvironment to promote protein–lipid and protein–protein interactions. We purified lipid rafts from human frontal
cortex from normal, early motor stages of Parkinson’s disease (PD) and incidental Parkinson’s disease (iPD) subjects and analyzed
their lipid composition. We observed that lipid rafts from PD and iPD cortices exhibit dramatic reductions in their contents of n-3
and n-6 long-chain polyunsaturated fatty acids, especially docosahexaenoic acid (22:6-n3) and arachidonic acid (20:4n-6). Also,
saturated fatty acids (16:0 and 18:0) were significantly higher than in control brains. Paralleling these findings, unsaturation and
peroxidability indices were considerably reduced in PD and iPD lipid rafts. Lipid classes were also affected in PD and iPD lipid rafts.
Thus, phosphatidylserine and phosphatidylinositol were increased in PD and iPD, whereas cerebrosides and sulfatides and plas-
malogen levels were considerably diminished. Our data pinpoint a dramatic increase in lipid raft order due to the aberrant bio-
chemical structure in PD and iPD and indicate that these abnormalities of lipid rafts in the frontal cortex occur at early stages of
PD pathology. The findings correlate with abnormal lipid raft signaling and cognitive decline observed during the development
of these neurodegenerative disorders.
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bral cortex with disease progression
(13–15).
However, an important aspect is that
altered cortical function is not related to
the presence of LB and LN in the cere-
bral cortex (16). Therefore, factors other
than the accumulation of abnormal α-
synuclein in the form of LB and LN are
causative of the abnormal cortical func-
tion (17). Molecular neuropathology has
elucidated a series of modifications that
may result in impaired function of se-
lected metabolic pathways, these includ-
ing altered mitochondrial function, gly-
colysis and protein degradation
pathways in the frontal cortex in PD and
iPD (17,18). There is some agreement
that molecular damage in PD is due to
oxidative stress, which enhances oxida-
tive DNA damage and increases the ex-
pression levels of lipoxidation, nitration
and glycoxidation markers and lipid per-
oxides and increases the expression of
RAGE (advanced glycation end products
receptor) in the frontal cortex of PD and
iPD (19–21).
Recent evidence has demonstrated
that molecular alterations in PD are not
limited to specific proteins but also to
abnormal levels of fatty acids in the
frontal cortex in iPD and PD compared
with age-matched controls. Thus, the
highly peroxidizable docosahexaenoic
acid (DHA) appears to be significantly
increased in the frontal cortex in iPD
and PD (20). Whether altered lipid com-
position affects highly specialized struc-
tures such as lipid rafts in PD and iPD is
not known. Lipid rafts are membrane
microdomains characterized by their
high content in sphingolipids, choles-
terol and saturated fatty acids, as well as
by reduced content in polyunsaturated
fatty acids (PUFAs). These micro -
domains provide a highly saturated and
liquid-ordered physicochemical micro -
environment that promotes protein–lipid
and protein–protein interactions (22–24).
Lipid rafts comprise a highly dynamic
clustering of proteins and lipids that
play a central role in signal transduction
and intercellular communication. Their
alterations have been associated with al-
tered neuronal function, synaptic trans-
mission and neurotransmitter signaling
(17,25–27). We have recently demon-
strated that lipid composition, in partic-
ular, long-chain polyunsaturated fatty
acids (LCPUFAs), are profoundly altered
in the frontal cortex of late stages of Alz-
heimer’s disease (28), which presumably
would underlie, at least in part, neu-
ronal dysfunction and cognitive deterio-
ration. However, potential alterations in
the lipid structure and spatial organiza-
tion of lipid rafts in PD have not been
explored to date. In the present study,
we aimed at isolating highly purified
lipid rafts from human frontal cortex
from control, PD and iPD subjects to an-




Human samples analyzed in the pres-
ent study are summarized in Table 1
and include eight cases with PD (group
PD: five males and three females, aver-
age age 73.9 years), eight cases with in-
cidental PD (group iPD: six males and
two females, average age 72.7 years)
and 11 age-matched controls (group No
Significant Lesions [NSL]: five males
and six females, average age 75.5 years).
Control cases had no neurological
symptoms and signs, and the neu-
ropathological examination did not
show abnormalities. Cases with PD
showed a short history of motor symp-
toms. Modified Hoehn and Yahr staging
was between 1.5 (unilateral plus axial
involvement) and 2.5 (mild bilateral dis-
ease with recovery on pull test). The se-
lection of PD cases with relatively mild
or moderate motor symptoms was made
to minimize changes related to a long
course of the disease and the concomi-
tant combination of variegated drugs
used for the treatment. Cases with iPD
did not complain of neurological
deficits, although PD- related lesions
were found in the neuropathological
postmortem study. The causes of death
in both groups were similar and in-
cluded infectious diseases (mainly
pneumonia), heart infarction and
 carcinoma.
At autopsy, one cerebral hemisphere,
alternate sections of the brain stem and
one cerebellar hemisphere were fixed in
buffered formalin and processed for neu-
ropathological study. The other hemi-
sphere, cut on coronal sections 1-cm
thick, alternate sections of the brain stem
and sections of the cerebellum were im-
mediately stored at –80°C until use for
biochemical studies. The time of post-
mortem delay varied between 2 h,
15 min, and 10 h, 50 min. The neu-
ropathological diagnosis and staging was
carried out according to well-established
criteria for Alzheimer’s disease, PD and
argyrophilic grain disease (9,29).
Lipid Raft Isolation
Lipid raft fractions from cortical gray
matter were isolated following the pro-
tocol described by Mukherjee et al. (30)
with slight modifications (28). Briefly, 
0.1 g frontal cortex gray matter was ho-
mogenized at 4°C in 8 vol of isolation
buffer (50 mmol/L Tris-HCl, pH 8.0,
10 mmol/L MgCl2, 20 mmol/L NaF,
1 mmol/L Na3VO4, 5 mmol/L 
β-mercaptoethanol and 1 mmol/L
PMSF) and a cocktail of protease in-
hibitors (Roche Diagnostics, Barcelona,
Spain) containing 1% Triton X-100 and
5% glycerol in a glass homogenizer for 
5 min and then centrifuged at 500g for
another 5 min. About 800 μL of the su-
pernatant was mixed with an equal vol-
ume of 80% sucrose in isolation buffer
and overlayed with 7.5 mL of a 36%
 sucrose solution and 2.7 mL of a 15% su-
crose solution in isolation buffer, in 
10-mL ultracentrifuge tubes (Ultraclear,
Beckman). Sucrose gradients were cen-
trifuged at 150,000g for 18 h at 4°C
using a Beckman SW41Ti rotor. Then
2-mL fractions were collected from the
top to the bottom, and the final pellet,
corresponding to nonraft fractions, was
collected and resuspended in 2 mL isola-
tion buffer. All fractions were frozen at
–80°C until analyses. Purity of lipid rafts
(fraction 1) was assessed by analyses of
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protein markers and lipid composition
(see below).
Western Blot Analyses
For protein characterization of lipid
rafts, all fractions were resolved on
sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE) and in-
cubated with different antibodies di-
rected to raft (caveolin-1 and flotillin-1),
nonraft (Na+/K+ ATPase α1 subunit and
clathrin heavy chain), cytosolic (Cu/Zn
superoxide dismutase, SOD-1) and mito-
chondrial (Mn superoxide dismutase,
SOD-2) markers.
Equal volumes of all fractions isolated
were resuspended in SDS loading buffer
(625 mmol/L Tris-HCl, pH 6.8; 1% SDS;
10% glycerol; 5% β-mercaptoethanol;
0.01% bromophenol blue) and boiled at
95°C for 5 min to avoid protein aggre-
gates. Protein contents were quantified
by the bicinchoninic acid assay (BCA,
Fisher Scientific, Madrid, Spain). Sam-
ples were run on SDS-PAGE, transferred
to polyvinylidene fluoride (PVDF) trans-
fer membranes (GE Healthcare) and
processed for immunoblotting with the
different lipid raft and nonraft markers
used in this study. Membranes were first
incubated with mouse monoclonal
anti–caveolin-1 antibody (BD Transduc-
tion, 1:500) and then incubated with the
corresponding horseradish peroxidase
(HRP)-linked antimouse antibody
(1:5,000). Afterward, the same membrane
was successively reblotted with the anti-
bodies specifically directed to flotillin-1
(BD Biosciences, 1:500), Na+/K+ ATPase
α1 subunit (Santa Cruz Biotechnology,
1:1,000), clathrin heavy chain (BD Trans-
duction 1:1,000), superoxide dismutase-1
(SOD-1, Novocastra, 1:1,000) and super-
oxide dismutase-2 (SOD-2, StressGen,
1:5,000), followed by incubation with the
corresponding HRP-linked secondary
antibodies. When required, before reblot-
ting, antibody stripping was performed
by incubating the PVDF membrane in
stripping buffer (2% SDS, 100 mmol/L
β-mercaptoethanol, 50 mmol/L Tris,
pH 6.8) at 50°C for 30 min with gentle
agitation. Then membranes were rinsed
several times before incubation with an-
tibodies. Finally, the specific antibody
signals were visualized by using the en-
hanced chemiluminescence (ECL) kit (GE
Healthcare, Spain), followed by apposition
of the membranes to autoradiographic
films (GE Healthcare, Spain).
Lipid Analyses
Total lipids were extracted with
 chloroform/methanol (2:1 v/v). The or-
ganic solvent was evaporated under a
stream of nitrogen, and the lipid content
was determined gravimetrically and
stored in chloroform/methanol (2:1 v/v)
containing 0.01% of butylated hydroxy-
toluene (BHT) as an antioxidant (31).
Lipid classes were separated from a frac-
tion of total lipid by one-dimensional
double development high-performance
thin-layer chromatography using methyl
acetate/isopropanol/chloroform/
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Table 1. Summary of cases.
Case Age Sex Postmortem delay Neuropathology
NSL
1 78 M 2 h 15 min No lesions
2 79 M 7 h No lesions
3 85 M 5 h 45 min ADII/A, status cribosus
4 70 M 13 h ADI/A
5 71 M 12 h Lacunes
6 73 F 5 h 30 min ADI/0
7 82 F 11 h ADI/A
8 75 F 3 h ADI/A, status cribosus
9 69 F 2 h 30 min ADI/0
10 66 F 8 h No lesions
11 65 F 4 h No lesions
PD
12 70 M 9 h PD4, ADII/B, lacunes
13 68 M 4 h 45 min PD4, ADIII/A, lacune
14 76 M 4 h 30 min PD4
15 85 M 3 h 15 min PD4, ADIII/A, status cribosus
16 69 M 5 h 55 min PD4, ADI/A
17 74 F 10 h 15 min PD3, ADII/0, AGD1, status cribosus
18 70 F 10 h 50 min PD3, ADII/A
19 70 F 5 h 15 min PD4, ADII/A
iPD
20 72 M 8 h 55 min PD1, ADII/A
21 74 M 10 h 50 min PD1, ADII/0, AGD3
22 83 M 3 h 30 min PD2, ADIII/A, AGD3
23 83 M 4 h 30 min PD2, ADII/A, AGD1
24 67 M 2 h 30 min PD3, ADI/0
25 78 M 10 h 45 min PD3, ADI/0
26 77 F 3 h 15 min PD1, ADII/A, lacunes
27 70 F 10 h 50 min PD3, ADI/A, lacunes
NL, no lesions; 1–4 refer to Braak stages of PD-related pathology. ADI, ADII and ADIII refer to
Braak stages of neurofibrillary tangle pathology; 0, A and B refer to Braak stages of 
β amyloid plaques; AGD, argyrophilic grain disease; 1, 2 and 3 refers to AGD stages. Cases
1–11 had not suffered from neurological deficits, and the neuropathological examination
did not reveal brain lesions. Cases 12–19 had suffered from PD, and the neuropathological
examination revealed the presence of LB in selected brain stem nuclei and the limbic
system but not in the cerebral neocortex. Cases 20–27 did not refer neurological deficits
but showed LB in the medulla oblongata, pons and substantia nigra (depending on the
stage), but neuron loss in the substantia nigra did not exceed the 50% of the total number
of neurons in the pars compacta. Cases 1–11 were considered as controls cases 12–19 as
PD with Parkinsonism and cases 20–27 as incidental PD.
methanol/ 0.25% (w/v) KCl (5:5:5:2:1.8
by volume) as the developing solvent
system for the polar lipid classes and
hexane/diethyl ether/acetic acid
(22.5:2.5:0.25 by volume) as the develop-
ing solvent system for the neutral lipid
classes (31). Lipid classes were quantified
by charring with 3% (w/v) aqueous
cupric acetate containing 8% (v/v) phos-
phoric acid followed by calibrated scan-
ning densitometry using a Shimadzu CS-
9001PC dual-wavelength spot scanner.
Equal amounts of total lipids were used
in all analyses.
Lipids from cortical gray matter and
from lipid rafts and nonrafts fractions
were subjected to acid-catalyzed trans-
methylation for 16 h at 50°C, using 1 mL
toluene and 2 mL 1% sulfuric acid (v/v)
in methanol. The resultant fatty acid
methyl esters were purified by thin-layer
chromatography and visualized under
spraying with 1% iodine in chloroform
(31). Fatty acid methyl esters were sepa-
rated and quantified by using a Shi-
madzu GC-14A gas chromatograph
equipped with a flame ionization detec-
tor (250°C) and a fused silica capillary
column Supelcowax™ 10 (30 m ×
0.32 mm internal diameter). Individual
fatty acid methyl esters were identified
by referring to authentic standards.
Statistical Analyses
Comparison between groups was as-
sessed either by one-way analysis of var-
iance followed by the Tukey post hoc test
or Kruskal-Wallis test followed by the
Games-Howell post hoc test, depending
on the homocedasticity and normality of
experimental data. Results illustrated in
Figure 4 and Table 2 were assessed using
the Student t test. Data were arcsin trans-
formed (percent lipid content) to attain
the assumption of normality. Pearson
correlation coefficients were used to ex-
press bivariate relationships between
fatty acids and lipid classes. Multivariate
statistics were performed using discrimi-
nant function analysis. Predictive vari-
ables were chosen according to the num-
ber of cases in each group to fulfill the
assumptions of discriminant analysis
(32). Individual canonical scores for each
case and centroids were calculated using
the SPSS statistical package, and the re-
sults were plotted to predict to which
group a particular individual case be-
longed.
RESULTS
Characterization of Lipid Rafts from
Normal Human Frontal Cortex
We first tested for the purity of lipid
rafts isolated from the frontal cortex of
human brains from control, PD or iPD,
using different lipid raft and nonraft
markers in immunoblotting assays. Thus,
specific antibodies directed to lipid raft
markers, caveolin-1 and flotillin-1 were
used to identify raft-enriched fractions,
observing that these two markers were
mostly present in fraction 1 (Figure 1A).
The same membranes were then used to
reblot with antibodies directed to
Na+/K+ ATPase α1 subunit and clathrin
heavy chain, two proteins highly repre-
sented in nonraft fractions of the plasma
membrane, observing that these antibod-
ies recognized some bands exclusively in
fractions 5 and 6. Similarly, cytosolic and
mitochondrial markers SOD-1 and SOD-2,
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Table 2. Lipid class comparison between lipid rafts and nonraft membranes in control
subjects (NSL).
Nonrafts Lipid rafts
Sphingomyelin 1.97 ± 0.86 11.43 ± 1.44a
PC 9.86 ± 0.87 5.35 ± 0.49a
PS 10.85 ± 1.08 6.82 ± 0.50a
PI 3.67 ± 0.59 2.16 ± 0.17a
Phosphatidylglycerol 2.71 ± 0.58 0.70 ± 0.10a
PE 28.72 ± 1.82 20.97 ± 0.57a
Sulfatides 0.00 ± 0.00 10.56 ± 0.68a
Cerebrosides 0.00 ± 0.00 5.10 ± 0.79a
Cholesterol 27.68 ± 1.98 33.04 ± 1.18a
Free fatty acids 10.68 ± 0.92 2.17 ± 0.28a
Sterol esters 0.00 ± 0.00 1.68 ± 0.60a
Total neutral lipids 42.23 ± 2.66 36.90 ± 1.41
Total polar lipids 57.77 ± 2.66 63.09 ± 1.41
Phospholipid/cholesterol 2.15 ± 0.18 1.11 ± 0.06a
Results are expressed as mole % and represent mean ± SEM.
aP < 0.05 compared with nonrafts.
Figure 1. Western blot analyses of protein markers in fractions 1–6 from NSL, PD and PDi
brain cortices. Equal amounts of total protein were used for NSL, PD and iPD samples.
Standard molecular weight values are indicated (left).
respectively, were present in fractions 5
and 6 but absent in fractions 1–4. There-
fore, fraction 1 was selected for lipid
analyses.
Lipid class analyses of lipid rafts from
control subjects are detailed in Table 2.
The results revealed a high content of
sphingomyelin (11.4% ± 1.4%), choles-
terol (33.0% ± 1.2%) and saturated fatty
acids (53.86% ± 1.53%, shown in Table 3),
which is consistent with the notion that
lipid rafts are sphingomyelin- and
 cholesterol-enriched membrane micro -
domains containing high levels of satu-
rated acyl chains. Within phospholipid
groups, phosphatidylethanolamine (PE)
was the most abundant (21% ± 0.6%)
glycerophospholipid, followed by phos-
phatidylserine (PS) (6.8% ± 0.5%), phos-
phatidylcholine (PC) (5.3% ± 0.5%) and
phosphatidylinositol (PI) (2.2% ± 0.2%).
Glycosphingolipid sulfates (sulfatides)
and monoglycosylceramides (cerebro-
sides) were also present in significant
amounts in lipid rafts (10.6% ± 0.7% and
5.1% ± 0.8%, respectively). Comparison
of lipid classes between lipid raft and
nonraft fractions from control subjects
(Table 2) confirmed the heterogeneous
distribution of lipids between these two
membrane domains. Thus, sphin-
gomyelin content in nonraft fractions
was around 17% that observed in lipid
rafts (Table 2). Likewise, cholesterol in
lipid rafts was significantly higher than
in nonrafts (Table 2). Among phospho-
lipids, nonraft fractions displayed higher
contents of PC, PE, PS and PI than lipid
raft fractions. Consequently, the phos-
pholipid-to-cholesterol ratio was consid-
erably higher in nonrafts (2.15) than in
lipid rafts (1.11). Taken together, the out-
comes from protein and lipid analyses
confirm the high purity of lipid rafts iso-
lated from brain cortex.
Individual fatty acid contents of lipid
rafts from control subjects (group NSL)
shown in Table 3 revealed the presence
of significant contents of monoene fatty
acids (principally oleic acid, 18:1n-9)
and n-3 LCPUFA, specifically DHA
(22:6n-3), whereas eicosapentaenoic acid
(20:5n-3) level was negligible. PUFAs of
the n-6 series accounted for 6.35% of
total lipid raft fatty acids, of which
arachidonic acid (AA) (22:4n-6) was the
main constituent. Lipid rafts also exhib-
ited significant amounts of dimethyl ac-
etal (DMA) fatty acids, in particular,
18:0 DMA and 16:0 DMA. These ether
fatty acids are formed exclusively from
neutral plasmalogens upon acidic trans-
esterification methods used to prepare
fatty acid methyl esters (as used here).
In the plasmalogen molecule, the
aliphatic moieties at the sn-1 position
consist of C18:0 (and to a lesser extent,
C16:0 and C18:1-n9) carbon chains form-
ing a vinyl-ether bond, whereas the sn-2
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Table 3. Fatty acid composition of lipid rafts from control subjects, PD and iPD.
NSL PD iPD
Fatty acids
14:0 0.52 ± 0.04 0.62 ± 0.07 0.58 ± 0.04
14:1 0.13 ± 0.10ab 0.18 ± 0.08a 0.00 ± 0.00b
15:0 0.91 ± 0.14ab 1.42 ± 0.06a 0.42 ± 0.15b
15:1 0.10 ± 0.03a 0.17 ± 0.04a 0.00 ± 0.00b
16:0 DMA 1.82 ± 0.25 1.73 ± 0.26 1.44 ± 0.15
16:0 24.10 ± 1.31b 28.66 ± 2.07ab 31.98 ± 1.06a
16:1 1.08 ± 0.08b 3.94 ± 0.63a 1.17 ± 0.13b
16:2 0.20 ± 0.03b 0.53 ± 0.21ab 0.39 ± 0.02a
17:0 0.31 ± 0.01a 0.36 ± 0.02a 0.05 ± 0.03b
17:1 0.05 ± 0.02b 0.35 ± 0.12a 0.00 ± 0.00b
18:0 DMA 3.47 ± 0.11a 1.54 ± 0.20b 3.75 ± 0.27a
18:1n-9 DMA 0.76 ± 0.13a 0.84 ± 0.09a 0.29 ± 0.05b
18:1n-7 DMA 1.49 ± 0.38a 0.79 ± 0.16ab 0.56 ± 0.12b
18:0 22.05 ± 0.43b 26.35 ± 0.73a 28.18 ± 0.65a
18:1 n-9 17.64 ± 1.10a 14.88 ± 1.33a 10.09 ± 0.53b
18:2 n-6 0.85 ± 0.09a 0.38 ± 0.06b 0.50 ± 0.10b
20:1 1.08 ± 0.19 1.25 ± 0.19 0.68 ± 0.09
20:2 n-6 0.13 ± 0.04 0.07 ± 0.04 0.04 ± 0.03
20:3 n-6 0.53 ± 0.02a 0.31 ± 0.05b 0.44 ± 0.06ab
20:4 n-6 3.70 ± 0.18a 1.47 ± 0.12b 1.26 ± 0.26b
22:2 n-6 0.68 ± 0.09b 2.77 ± 0.36a 1.63 ± 0.28b
23:0 2.40 ± 0.12a 1.21 ± 0.12b 1.32 ± 0.12b
22:5 n-6 0.46 ± 0.06a 0.09 ± 0.04b 0.08 ± 0.04b
22:5 n-3 0.14 ± 0.03a 0.06 ± 0.03ab 0.01 ± 0.01b
22:6 n-3 6.87 ± 0.34a 1.71 ± 0.22b 1.41 ± 0.41b
Totals
Saturates 53.86 ± 1.53b 61.04 ± 2.41a 66.96 ± 1.56a
n-3 7.11 ± 0.37a 2.10 ± 0.24b 1.95 ± 0.47b
n-6 6.35 ± 0.24a 5.11 ± 0.48b 4.18 ± 0.20b
n-9 19.63 ± 1.26a 17.33 ± 1.27a 10.88 ± 0.58b
n-3 LCPUFA 7.11 ± 0.37a 2.10 ± 0.24b 1.91 ± 0.46b
Monoenes 28.92 ± 1.65a 29.21 ± 2.53a 21.18 ± 0.97b
Ratios
n-3/n-6 1.12 ± 0.05a 0.42 ± 0.03b 0.45 ± 0.08b
18:1/n-3 LCPUFA 2.57 ± 0.22b 8.26 ± 1.81a 7.35 ± 1.77a
Saturates/n-3 7.75 ± 0.40b 31.62 ± 3.43a 47.01 ± 9.72a
Saturates/n-9 2.91 ± 0.26b 3.71 ± 0.37b 6.28 ± 0.36a
Indices
Unsaturation index 93.73 ± 5.07a 57.35 ± 2.47b 44.86 ± 3.52c
Peroxidability index 73.88 ± 3.35a 26.70 ± 2.41b 23.08 ± 4.48b
Results are expressed as mole % and represent means ± SEM. Values in the same row
bearing different letters are significantly different (P < 0.05). Unsaturation and peroxidability
indices were calculated following the equations in Cosgrove et al. (63).
position is occupied by PUFAs, specifi-
cally AA or DHA (33,34). Therefore, the
amount of DMA fatty acids stoichiomet-
rically reflects that of plasmalogens,
being commonly used as a quantitative
measure of total plasmalogens, mainly
represented by the PE class (plas-
menylethanolamines) with rather less in
PC, and commonly little or none in
other phospholipids such as PI (33,35).
Lipid Composition of PD and iPD Lipid
Rafts
Results shown in Tables 3 and 4 reveal
that lipid rafts isolated from PD and iPD
frontal cortices exhibit profound alter-
ations in their lipid composition com-
pared with control healthy subjects. First,
lipid rafts from PD and iPD brains con-
tain significantly higher contents of satu-
rates (mainly 16:0 and 18:0) and lower
unsaturated fatty acids than age-matched
controls (as reflected in the unsaturation
and peroxidability indices) (Table 3). In
fact, the unsaturation index was reduced
by 38% in PD and 52% in iPD compared
with controls, indicating that lipid rafts
in PD and iPD are significantly more vis-
cous and liquid-ordered structures than
in controls.
Second, detailed analyses of unsatu-
rated fatty acids in PD and iPD lipid
rafts revealed abnormally low amounts
of LCPUFAs (Table 3). Thus, in PD sub-
jects, DHA (22:6n-3) and AA (22:4n-6)
were reduced by 75% and 60%, respec-
tively. Similar reductions were observed
in the levels of these two fatty acids in
iPD lipid rafts (79% and 66% for DHA
and AA, respectively). Interestingly, the
reduction of DHA in PD lipid rafts took
place without a compensatory increase in
docosapentaenoic acid (DPA) (22:5n-6).
Instead, DPA content was significantly
diminished by 80% in PD and 92% in
iPD brains. Also, linoleic acid (18:2n-6),
the metabolic precursor of AA, was sig-
nificantly reduced by 55% and 41% in
PD and iPD lipid rafts, respectively,
which might resemble a limited ability to
synthesize AA in degenerating nerve tis-
sue. Regarding monoenes, no statistical
differences were observed in the content
of oleic acid (18:1n-9) or in the total n-9
series in PD, although a reduction of 15%
in 18:1n-9 was evident. On the contrary,
18:1n-9 and n-9 fatty acids were consid-
erably diminished in iPD (around 43%
for both lipid parameters). As a conse-
quence, the ratios saturates/n-3, satu-
rates/n-9 and 18:1/n-3 were all dramati-
cally increased in PD and iPD lipid rafts,
whereas the ratio n-3/n-6 was signifi-
cantly reduced (Table 3). Also, PD and
iPD lipid rafts exhibited a considerably
reduced unsaturation index (that could
be entirely attributable to the reductions
in LCPUFAs) as well as a dramatic re-
duction in the peroxidability of mem-
brane lipids (63% and 68% in PD and
iPD, respectively).
Third, lipid classes were also affected
in PD and iPD lipid rafts (Table 4). Thus,
PE was found to be significantly in-
creased (12%) in PD lipid rafts (but not
in iPD), whereas PS and PI levels were
increased by 36% in iPD (but not in PD)
compared with control cases (Table 4).
Conversely, the amounts of cerebrosides
and sulfatides were dramatically re-
duced by 30% and 51%, respectively, in
iPD (but not in PD). In addition, clear
trends were also observed for the reduc-
tion in sphingomyelin and the increase
in PC in PD and iPD frontal cortex lipid
rafts, although in these cases, changes
were not statistically significant. In view
of these findings, the alteration of lipid
classes from lipid rafts was considerably
more pronounced in iPD than in PD. As
a consequence of the alterations in the
contents of PE, PC and PS, the propor-
tion of phospholipids to cholesterol in
the lipid rafts from frontal cortex of PD
and iPD brains appeared increased
when compared with control subjects
(Table 4), indicating a net reduction in
the proportion of cholesterol in mem-
brane rafts.
Regarding lipid rafts protein markers,
there were no significant changes of
flotillin or caveolin contents in lipid rafts
from PD or iPD compared with age-
matched controls, a finding that indi-
cates that resident protein contents of
rafts remained unaffected in PD or iPD
(Figure 1).
We have also explored the relevant bi-
variate relationships between lipid
classes and fatty acids in control, PD and
iPD lipid rafts. The results indicate that
PD-induced neurodegeneration is accom-
panied by altered relationships between
n-3 or n-6 and main LCPUFAs contain-
ing phospholipids (Figure 2). Thus, the
observed linear association between PS
and AA (Figure 2A) or DHA (Figure 2B)
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Table 4. Lipid class composition of lipid rafts from control subjects, PD and iPD.
NSL PD iPD
Sphingomyelin 11.43 ± 1.44 8.05 ± 0.64 10.30 ± 1.52
PC 5.35 ± 0.49 6.42 ± 0.49 7.11 ± 0.76
PS 6.82 ± 0.50b 7.54 ± 0.55ab 9.31 ± 0.46a
PI 2.16 ± 0.17b 2.20 ± 0.20b 3.00 ± 0.24a
Phosphatidylglycerol 0.70 ± 0.10 0.86 ± 0.19 1.09 ± 0.21
PE 20.97 ± 0.57b 23.54 ± 0.36a 22.14 ± 0.53ab
Sulfatides 10.56 ± 0.68a 10.35 ± 0.98ab 7.37 ± 0.84b
Cerebrosides 5.10 ± 0.79a 5.98 ± 0.69a 2.52 ± 0.60b
Diacylglycerols 0.00 ± 0.00 0.00 ± 0.00 0.0 ± 0.0
Cholesterol 33.04 ± 1.18 30.43 ± 1.17 35.16 ± 1.96
Free fatty acids 2.17 ± 0.28a 2.70 ± 0.32a 0.88 ± 0.31b
Triglycerides 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
Sterol esters 1.68 ± 0.60 1.94 ± 0.31 1.11 ± 0.57
Neutral lipids 36.90 ± 1.41 35.08 ± 1.23 37.15 ± 1.35
Polar lipids 63.09 ± 1.41 64.92 ± 1.23 62.85 ± 1.35
Phospholipid/cholesterol 1.11 ± 0.06b 1.35 ± 0.09a 1.26 ± 0.12ab
Results are expressed as mole % and represent means ± SEM. Values in the same row
bearing different letters are significantly different (P < 0.05).
in control subjects (r = 0.792, P < 0.01,
and r = 0.603, P < 0.05, respectively)
completely disappeared in PD and iPD.
The same applies to the relationship be-
tween PI and DHA (r = 0.815, P < 0.01 in
control rafts), which vanished in PD and
iPD (Figure 2D). These changes are spe-
cific for LCPUFAs, since other relation-
ships, such as saturates (namely 16:0 +
18:0) versus PC (Figure 2C) or PS (not
shown), remained unaffected in the neu-
ropathological lipid rafts. Despite most
alterations in bivariate lipid relationships
being similar in PD and iPD, some differ-
ences could be detected between these
two pathologies. Thus, there appeared to
be a gradual change in the relationships
between plasmalogen-associated 18:0
DMA and AA consisting on a progres-
sive diminution of regression slopes with
NSL (s = 1,245, r = 0.667, P < 0.05) > PD
(s = 0.512, r = 0.780, P < 0.05) > iPD (s =
–0.347, r = –0.014, P > 0.05) (Figure 2E). A
similar interesting finding was observed
for the saturated 18:0 versus monounsat-
urated 18:1n-9 relationship (Figure 2F),
where NSL (s = –2.383, r = –0.907, P <
0.01) < PD (s = –1.335, r = –0.900, P <
0.01) < iPD (s = –0.072, r = 0.16, P > 0.05).
We also performed discriminant anal-
ysis on lipid raft composition to assess
whether lipid composition per se could
provide a predictive determination of
the pathological state. Our results
showed that the contribution to overall
variance of the first and second canoni-
cal functions was 72.0% (χ2 = 87.15, P <
0.001) and 28.0% (χ2 = 35.22, P < 0.001),
respectively. The combination of first
and second discriminant functions
clearly separates the NSL group from
the PD and iPD groups (Figure 3). Struc-
ture matrix revealed that the variables
that showed the highest absolute corre-
lation (around ±0.3) with respect to
every discriminate function were DHA,
AA, 22:5n-6 and 18:1-n9 (for the first dis-
criminant function), whereas the second
function (which allows a neat discrimi-
nation between PD and iPD) was de-
fined by the 18:0 DMA and cerebroside
contents. One important outcome from
this analysis was that PD and iPD
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Figure 2. Linear relationships for a subset of lipid parameters in lipid rafts from NSL, PD and
iPD frontal cortices. Correlation coefficients and statistical significance are indicated in
the text. Units are expressed as mole percentage for all variables.
Figure 3. Discriminant function analyses of groups NSL, PD and iPD. In the scatterplot, cen-
troids are represented (). Table in the right panel shows the variable matrix structure for
each canonical function. For details and interpretation, see Results and Discussion.
groups could be resolved in the two-
 dimensional plot on the basis of subtle
differences on gross fatty acids and lipid
class composition.
Lipid Composition of Frontal Brain
Cortex
To obtain a macroscopic view of the
changes in lipid composition in control
and PD, we also performed lipid analy-
ses on frontal cortex phospholipids from
the same control and PD samples where
lipid rafts were obtained. The main re-
sults are summarized in Figure 4 as per-
centage of change in PD compared with
NSL. As it can be seen, no changes were
observed in the proportion of phospho-
lipids in the frontal gray matter between
NSL and PD. However, a significant re-
duction in sphingomyelin (–35.7%), sul-
fatides (–12.8%) and cerebrosides
(–27.8%) was evident in the PD cortex
(Figure 4A). Regarding fatty acids, the
results showed increased levels of AA
(+21.4%) and DHA (+49.5 %) in PD cor-
tex compared with age-matched con-
trols (Figure 4A). Likewise, DPA (22:5n-
6) content and peroxidability index
were significantly augmented in the PD
cortex, whereas total saturates (18:0 and
16:0), 18:1n-9 and 18:0 DMA (an index
of plasmalogen content, see below) re-
mained unaltered compared with con-
trol subjects. These results demonstrate
that, while in whole cortical gray matter
from PD brains levels of LCPUFAs are
increased, in particular for DHA, their
presence in lipid rafts are dramatically
reduced, indicating the complexity of
the deregulation cell membrane lipid
metabolism during the development 
of PD.
To get a deeper insight into the molec-
ular alterations in PD nerve cell mem-
branes, we analyzed the relationship be-
tween individual lipid species in lipid
raft and cortex in NSL and PD brains
(Figure 4B) case by case. The results
showed that, as expected, the sphin-
golipids and cholesterol ratios were con-
siderably increased in lipid rafts com-
pared with cortical tissues in both
groups. Other lipid classes appeared
equally distributed between lipid rafts
and total cortex from either group (that
is, total phospholipids), but fatty acids
were dramatically affected in PD (Fig-
ure 4B). Thus, the ratios for AA, DHA,
DPA and 18:0 DMA (as well as total n-3,
total n-6 PUFA and peroxidability
index) were considerably reduced in PD
compared with NSL subjects. Moreover,
because saturated fatty acids were sig-
nificantly higher in NSL lipid rafts, the
ratio saturates/n-3 LCPUFAs suffered a
spectacular increase (more than six-fold)
in PD.
DISCUSSION
The existence of lipid alterations in
PD, especially in the cortex, has been
poorly studied. Only a few studies have
addressed the biochemical status of brain
lipids in PD and related diseases, and
none have previously assessed the extent
of such lipid alterations in the molecular
structure of lipid rafts from the neocor-
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Figure 4. (A) Comparative analyses of main lipid classes and fatty acid contents and rele-
vant indices between control and PD frontal cortex gray matter. Results are expressed as
percent of change versus NSL group. Eight cases were analyzed in each group. *P < 0.1
and P < 0.05, respectively. (B) Analyses of the lipid raft-to-cortex ratios for representative
lipid classes and fatty acid contents as well as for representative indices in the NSL and
PD groups. Cortical and lipid raft were processed individually for each case. *P < 0.05, 
**P < 0.01 and ***P < 0.005 compared with NSL group.
tex. In the present work, we isolated and
characterized highly purified lipid rafts
from the human frontal cortex. Our data
show that lipid rafts from control, PD
and iPD subjects are enriched in sphin-
gomyelin, cholesterol and saturated fatty
acids compared with nonraft fractions.
Likewise, protein markers flotillin-1 and
caveolin-1 were only detected in fraction
1, which correspond to the lipid rafts
fraction. These characteristics fit per-
fectly with the widely assumed composi-
tion of lipid rafts in cell membranes in-
cluding nerve cells (22–24).
Interestingly, no differences were ob-
served in any of the lipid raft protein
markers or in the contents of sphin-
gomyelin or cholesterol between control
and iPD and PD, indicating that the basic
supporting structure of lipid rafts re-
mained unaltered in the frontal cortex of
subjects suffering from either neurode-
generative disease. However, we cannot
discard the possibility that impaired
 protein–protein and/or lipid–protein in-
teractions may take place in these micro -
structures of PD neurons, since it has
been claimed for other neuropathologies
such as Alzheimer’s disease (36). Con-
versely, our analyses point to massive
modification of fatty acid contents in
polar lipids from lipid rafts in PD and
iPD. Thus, n-6 PUFA levels (principally
AA and its metabolic precursor linoleic
acid) were dramatically reduced both in
PD and iPD (>60% for AA) compared
with age-matched control subjects and,
indeed, n-3 LCPUFA levels (mainly
DHA) were reduced even to a larger ex-
tent (>75%), but without concomitant in-
crease in DPA, which represented a
minor component of total fatty acids in
all groups. Significant reductions of
monoene 18:1n-9 were also detected in
lipid rafts from PD and iPD lipid rafts,
and these alterations occurred in combi-
nation with significant increases in
stearic acid (18:0). The stoichiometric
consequence of these changes is that the
significant negative relationship between
18:0 and 18:1n-9 observed in lipid rafts
from healthy brains is progressively re-
duced in PD and completely absent in
iPD samples (Figure 2F). Such a relation-
ship is physicochemically relevant, since
the ratio between both fatty acids repre-
sents an evolutionary conserved mecha-
nism to preserve the homeoviscous state
of cell membranes in response to differ-
ent forms of physical and/or chemical
stress (37,38). It can be surmised that the
significant increase in saturated 18:0 and
the reduction in 18:1n-9, along with a
disappearance of the relationship be-
tween 18:0 and 18:1n-9 in iPD lipid rafts,
may be indicative of a downregulation
of Δ9-desaturase, the enzyme responsi-
ble for the synthesis of n-9 monounsatu-
rated fatty acids from their saturated
precursors (39). This occurrence would
result in a concomitant loss of the ability
to adjust the lipid raft physical order.
Both aspects are currently under investi-
gation in our laboratories.
The abnormalities in the fatty acid pro-
files of PD and iPD lipid rafts provoke a
considerable reduction in the unsatura-
tion (>40%) and peroxidability indices
(>60%), also accompanied by dramatic
increases in saturates/n-3 (>300%) and
saturates/n-9 ratios (>30%), which indi-
cates that raft microdomains from PD
and iPD brain cortices are notably more
viscous and liquid ordered than in the
age-matched control group. Indeed, it
has been experimentally demonstrated
that n-3 LCPUFAs, mainly DHA, are in-
corporated into both cholesterol and
sphingolipid-rich detergent-resistant
 liquid-ordered (lo) and liquid-disordered
(ld) plasma membrane microdomains in
many cell types (40,41). However, the
poor affinity of DHA, and perhaps other
LCPUFAs for cholesterol, provides a
lipid-driven mechanism for lateral-
phase separation of cholesterol- and
sphingolipid-rich lipid microdomains
from the surrounding ld phase in model
membranes altering the size, physical
order, elastic compressibility, lateral seg-
regation and clustering of cell surface
lipid microdomains (42–44). Further-
more, it has been proposed that PUFA
impoverishment in microdomains may
have profound consequences on the dy-
namic partitioning of acylated proteins,
membrane fusion, rapid flip-flop, recep-
tor binding and resident protein func-
tion, thereby altering signal transduction
and neurotransmission (27,42,44).
Oxidative stress is considered to be
one of the key factors in the pathogenesis
of PD (45,46). Studies in the substantia
nigra and midbrain have shown in-
creased levels of lipid hydroperoxides
(47) and 4-hydroxy-2-nonenal (an end
product of lipid peroxidation) (48), as
well as changes in PUFAs susceptible for
lipid peroxidation, leading to increased
generation of malondialdehyde and hy-
droperoxides (20,49). Interestingly, oxida-
tive damage in the substantia nigra is
present in iPD (20). Only recently, evi-
dence for lipid peroxidation and oxida-
tive damage in cortical structures was
demonstrated in PD and iPD (20,50).
Further, studies performed in the neocor-
tex of subjects with iPD revealed the ex-
istence of oxidative damage, particularly
lipoxidation of different proteins (includ-
ing α-synuclein and Mn-superoxide dis-
mutase), advanced glycation and oxida-
tive DNA damage (as inferred by
increased 8-hydroxyguanine levels) in
early stages of PD neuropathology
(19,20), indicating the priming role of ox-
idative stress in the generation of the dis-
ease. In agreement, we found that oxida-
tive stress–related fatty acid
modifications (such as the reduction of
LCPUFAs and monoene contents, and
the depression of unsaturation and per-
oxidability indices), as well as the loss of
significant correlations between (i) PS
and AA or DHA, (ii) PI and DHA and
(iii) 18:0 and 18:1n-9, in lipid rafts from
frontal cortex in PD and iPD, point to the
generation of oxidative stress as a central
causative factor for lipid raft lipid dam-
age. The fact that most changes can be
observed in iPD indicates that lipid raft
lipid alterations represent early events in
the development of the pathology.
Nonetheless, changes affecting lipid
structure of lipid rafts in PD and iPD ap-
pear to indicate a more complex deregu-
lation of lipid metabolism than merely
oxidative stress–induced lipid oxidation.
Indeed, we have found that, compared
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with control cases, anionic phospholipid
PS and PI levels were increased by 36%
in iPD (but not in PD), whereas neutral
phospholipids remained unaffected. Fur-
ther, the amounts of cerebrosides and
sulfatides were dramatically reduced by
>30% in iPD (but not in PD). The reduc-
tion of sulfatides and cerebrosides would
affect nerve cell metabolism, since their
deficiency is associated with increased
ceramide production, which is formed
upon hydrolysis by sulfatidase and
galactsylcerebrosidase activities. Accu-
mulation of ceramide has deleterious bi-
ological results, including upregulation
of cytokines, generation of reactive oxy-
gen species, interruption of the mito-
chondrial respiratory chain and apopto-
sis (reviewed in [51]). Further, elevation
of ceramide and depletion of sulfatides
has contributed to the neurodegeneration
that occurs in Alzheimer’s disease (52).
Interestingly, the contents of lipid hall-
marks in lipid raft structure, namely
sphingolipids and cholesterol, remained
unaltered in PD and iPD. These changes
cannot be explained under an oxidative
stress framework exclusively, but indi-
cate that phospholipid metabolism was
selectively affected since the early stages
of the disease. It can be inferred that the
increase in LCPUFA-containing neutral
and anionic phospholipids (PE and PS,
respectively) might reflect a transient
compensatory mechanism involving
phospholipid synthesis linked to early
reduction in AA and DHA levels. In




ferase, and PS synthase have been found
to be elevated in the substantia nigra of
subjects suffering from idiopathic PD
(53), a finding that has been interpreted
as a compensatory response to repair
membrane phospholipids in nigrastriatal
neurons.
On the other hand, previous studies on
lipid composition of PD and iPD brains
have shown that highly peroxidable LCP-
UFAs, especially DHA, are not only not
reduced but are significantly increased in
PD frontal cortex (20), which has lead to
the hypothesis that DHA would be a
major source of lipoperoxides promoting
additional oxidative damage to cortical
neurons. The increase in DHA contents in
PD brains appeared to be restricted to the
frontal cortex, since no changes are pres-
ent in the amygdala, whereas a consider-
able reduction of DHA contents was ob-
served in the substantia nigra from the
same subjects (20). In principle, these ob-
servations in the frontal cortex are diffi-
cult to reconcile, with the results in this
study showing a reduction of DHA in
frontal cortex lipid rafts. Therefore, we
found it worthwhile to perform lipid
analyses on frontal cortex phospholipids
from the same samples where lipid rafts
were obtained. We could confirm in-
creased levels of DHA and AA in the PD
cortex compared with age-matched con-
trols (Figure 4A). Likewise, DPA (22:5n-6)
content and peroxidability index were
significantly augmented in the PD cortex,
whereas total saturates, monoenes and
18:0 DMA remained unaltered compared
with control subjects. Also, PD gray mat-
ter exhibited lower levels of sphin-
golipids, cerebrosides and sulfatides than
age-matched control subjects, but it is
noteworthy that levels of individual
phospholipids and cholesterol were simi-
lar to those of control brains.
Our results are well in agreement with
previous data published for frontal cor-
tex in PD pathology (20,54) and indicate
increased levels of peroxidable fatty
acids. These results demonstrate that,
while in whole cortical tissues from PD
brains, there are increased levels of LCP-
UFAs (particularly DHA), their presence
in lipid rafts was dramatically reduced.
The opposite trends of lipid alteration
between lipid rafts and brain cortex was
further explored by analyzing case by
case the content ratio (raft content/cortex
content) for each molecular species. The
outcomes of these analyses showed that
the ratios for AA, DHA, DPA and 18:0
DMA (as well as total n-3 and n-6
PUFAs) were considerably reduced in
PD compared with NSL subjects. These
data demonstrate a differential deregula-
tion of fatty acid metabolism and phos-
pholipid remodeling between distinct
membrane microdomains associated
with the progression of the disease.
The fact that major lipid changes in
PD and iPD frontal cortex lipid rafts af-
fect fatty acid contents in phospholipids
strongly indicates the abnormal function
or expression of deacylation-reacylation
enzymes during the development of
Parkinson’s diseases. These include
acyl-CoA synthetase (which converts
free fatty acids into acyl-CoA esters),
acyl-CoA:lysophospholipase acyltrans-
ferase (which catalyzes the transfer of
acyl groups from acyl-CoA to a
lysophospholipid acceptor) and phos-
pholipase A2 (which is responsible for
the hydrolysis of sn-2 fatty acids, espe-
cially AA and DHA, of a preexisting
glycerophospholipid with the formation
of a lysophospholipid) (55,56). A meta-
analysis of our data suggests the abnor-




which prefers polyunsaturated fatty
acyl-CoAs as acyl donors) and phos-
pholipase A2, which would explain the
reduction of DHA, DPA and AA con-
tents in lipid raft phospholipids. Inter-
estingly, cytosolic phospholipase A2
(cPLA2) activity was shown to be up-
regulated in several types of neurode-
generation, including spinal cord injury,
ischemic injury and Alzheimer’s dis-
ease (57). In addition, mice deficient in
cPLA2 activity are resistant to 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) neurotoxicity, an experimental
model of Parkinsonism, and this resist-
ance strongly suggests that cPLA2 is
closely associated with the pathophysi-
ology of PD (58). Also, our data indi-
cate that fatty acid metabolism in lipid
rafts and nerve cell membranes from
frontal cortex depends on the type of
membrane microdomain considered
(rafts versus nonrafts) and was pro-
foundly altered during the develop-
ment of PD pathology. In agreement,
fatty acid synthase was recently shown
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to be rate-limiting in production of
lipid molecules partitioning into Triton
X-100 or Lubrol- resistant membrane
 microdomains. It was also pointed out
that overexpression of fatty acid syn-
thase is linked to deregulation of raft
membrane composition and function
(59).
One important conclusion emerging
from our lipid raft analyses is the pres-
ence of significant amounts of dimethyl
acetals fatty acids (~7.5 % of total fatty
acids in polar lipids from NSL lipid
rafts), which correlates with that of plas-
malogens. One interesting property of
plasmalogens is that they have the abil-
ity to form nonlamellar structures and
can allow the transition of membranes
from a lamellar gel to liquid-crystalline
form. Obviously, these physical proper-
ties contribute to, or modulate, the for-
mation and/or maintenance of lipid
rafts (34). On the basis of these assump-
tions, the considerable reduction of
plasmalogen levels in PD strongly indi-
cates altered physicochemical properties
and protein–lipid dynamics within
frontal cortex lipid rafts in PD neu-
ropathology. Interestingly, in light of the
multivariate analyses performed here, it
can be concluded that subtle changes
observed in the plasmalogens (that is,
18:0 DMA) and cerebroside contents are
sufficient to discriminate between PD
and iPD lipid rafts. Moreover, it was
suggested that plasmalogens can act as
storage depots of DHA and AA given
their high levels in plasmalogens when
compared with their diacyl counterparts
(34,35). In agreement, we could demon-
strate that the impoverishment of plas-
malogens correlates with that of AA
(and DHA) in PD and iPD lipid rafts.
Given that AA is the precursor for
eicosanoid formation, its reduction
would affect signal transduction in the
frontal cortex.
Another crucial aspect whereby lipid
raft alteration might be involved in the
pathogenesis of PD is through its interac-
tion with α-synuclein. It was shown that
interaction with lipid rafts is essential for
the normal, presynaptic localization of α-
synuclein (60). The binding of α-synu-
clein to lipid rafts requires acidic phos-
pholipids, with a preference for PS
(60,61). Moreover, α-synuclein interac-
tion with lipid rafts requires a combina-
tion of PS with oleic (18:1n-9) and
polyunsaturated (either 20:4n-6 or 22:6n-
3) fatty acyl chains (61). Thus, according
to our present results, the depletion of
DHA and AA in PD and iPD lipid rafts
would force lipid rafts to exclude α-
synuclein from this microdomain, even-
tually altering the dynamics of the aggre-
gation/fibrillation state of α-synuclein
(62), likely facilitating the formation of
neurotoxic aggregates. Whether changes
in LCPUFAs in lipid rafts are the cause
or consequence of PD neurodegeneration
cannot be ascertained from the present
study but, in view of present results in
iPD, it might constitute an early
causative event.
In summary, our results demonstrate
the existence of massive lipid alterations
in lipid rafts from human frontal cortex
in PD and iPD. The marked reductions of
n-3 and n-6 LCPUFAs, plasmalogens and
unsaturation index, together with the in-
crease of saturated fatty acids, indicate
that lipid rafts in PD pathologies exist in
a notable viscous liquid-ordered state.
Such physicochemical alterations would
have a profound impact on lipid raft
thermodynamic properties, spatial or-
ganization and signal transduction. The
mechanisms responsible for the deregu-
lation of plasma membrane lipid metabo-
lism in PD appear to be complex and dif-
ferentially affect the lipid structure of
lipid rafts and other plasma membrane
domains.
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